BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Basnayake C, Kamm MA, Stanley A, Wilson-o'brien A, Burrell K, Lees-trinca I, Khera A, Kantidakis J, Wong O, Fox K, Talley NJ, Liew D, Salzberg MR, Thompson AJ. Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2020;5:890-9. [DOI: 10.1016/s2468-1253(20)30215-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther 2023;57:323-34. [PMID: 36544055 DOI: 10.1111/apt.17356] [Reference Citation Analysis]
2 Neshatian L, Carrington EV. Rectal Intussusception: Medical management and timing of the decision to operate. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100940] [Reference Citation Analysis]
3 Igualada-martinez P, Breslin E, Higgins D, Hainsworth A. Physiotherapy management of anorectal dysfunction. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100936] [Reference Citation Analysis]
4 Messner EM, Sturm N, Terhorst Y, Sander LB, Schultchen D, Portenhauser A, Schmidbaur S, Stach M, Klaus J, Baumeister H, Walter BM. Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores. J Med Internet Res 2022;24:e37497. [PMID: 36197717 DOI: 10.2196/37497] [Reference Citation Analysis]
5 Black CJ, Paine PA, Agrawal A, Aziz I, Eugenicos MP, Houghton LA, Hungin P, Overshott R, Vasant DH, Rudd S, Winning RC, Corsetti M, Ford AC. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 2022;71:1697-723. [PMID: 35798375 DOI: 10.1136/gutjnl-2022-327737] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Abdelghafar YA, Abdelqadir YH, Motawea KR, Nasr SA, Omran HAM, Belal MM, Elhashash MM, Abdelazim AA, Shah J. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.814] [Reference Citation Analysis]
7 Peters JE, Basnayake C, Hebbard GS, Salzberg MR, Kamm MA. Prevalence of disordered eating in adults with gastrointestinal disorders: A systematic review. Neurogastroenterol Motil 2022;34:e14278. [PMID: 34618988 DOI: 10.1111/nmo.14278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Markin KV, Temniy AV, Dnov KV. Efficacy of hypnotherapy in the treatment of irritable bowel syndrome. A systematic review with meta-analysis. Neurology bulletin 2022;LIV:44-55. [DOI: 10.17816/nb107881] [Reference Citation Analysis]
9 Sonneveld MJ, Hardeman S, Kuipers EJ, de Graaf W, Spaander MCW, van der Meer AJ. Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands. The Lancet Gastroenterology & Hepatology 2022;7:595-8. [DOI: 10.1016/s2468-1253(22)00164-9] [Reference Citation Analysis]
10 Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther 2022;56:110-20. [PMID: 35491477 DOI: 10.1111/apt.16939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
11 Rej A, Sanders DS, Aziz I. Further research needed to determine first-line therapy for IBS in primary care. Gut 2022:gutjnl-2022-328047. [PMID: 35732423 DOI: 10.1136/gutjnl-2022-328047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Berinstein JA, Fendrick AM. Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Aliment Pharmacol Ther 2022;55:1588-9. [PMID: 35610937 DOI: 10.1111/apt.16956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kindt S, Louis H, De Schepper H, Arts J, Caenepeel P, De Looze D, Gerkens A, Holvoet T, Latour P, Mahler T, Mokaddem F, Nullens S, Piessevaux H, Poortmans P, Rasschaert G, Surmont M, Vafa H, Van Malderen K, Vanuytsel T, Wuestenberghs F, Tack J. Belgian consensus on irritable bowel syndrome. AGEB 2022;85:360-382. [DOI: 10.51821/85.2.10100] [Reference Citation Analysis]
14 Sasegbon A, Hasan SS, Whorwell PJ, Vasant DH. Experience and clinical efficacy of gut‐directed hypnotherapy in an Asian population with refractory irritable bowel syndrome. JGH Open. [DOI: 10.1002/jgh3.12770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Masclee GM, Masclee AA, Kruimel JW, Conchillo JM, van Vliet J, Keszthelyi D. Using a Patient Hotel: Perceptions of the Quality of Care by Patients Undergoing Analysis for Gastrointestinal Motility Disorders in the Netherlands. J Patient Exp 2022;9:23743735221089453. [PMID: 35372681 DOI: 10.1177/23743735221089453] [Reference Citation Analysis]
16 Keefer L, Bedell A, Norton C, Hart AL. How Should Pain, Fatigue, and Emotional Wellness Be Incorporated Into Treatment Goals for Optimal Management of Inflammatory Bowel Disease? Gastroenterology 2022;162:1439-51. [PMID: 34995528 DOI: 10.1053/j.gastro.2021.08.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
17 Schwille-Kiuntke J, Ittermann T, Schmidt CO, Grabe HJ, Lerch MM, Völzke H, Rieger MA, Enck P, Schauer B. Quality of life and sleep in individuals with irritable bowel syndrome according to different diagnostic criteria and inflammatory bowel diseases: A comparison using data from a population-based survey. Z Gastroenterol 2022;60:299-309. [PMID: 35263783 DOI: 10.1055/a-1708-0277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Noble H, Hasan SS, Whorwell PJ, Vasant DH. The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID-19 pandemic. Neurogastroenterol Motil 2022;34:e14347. [PMID: 35238428 DOI: 10.1111/nmo.14347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Colomier E, Melchior C, Algera JP, Hreinsson JP, Störsrud S, Törnblom H, Van Oudenhove L, Palsson OS, Bangdiwala SI, Sperber AD, Tack J, Simrén M. Global prevalence and burden of meal-related abdominal pain. BMC Med 2022;20:71. [PMID: 35172840 DOI: 10.1186/s12916-022-02259-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu Q, Shi Z, Zhang T, Jiang T, Luo X, Su X, Yang Y, Wei W. Efficacy and Safety of Chinese Herbal Medicine Xiao Yao San in Functional Gastrointestinal Disorders: A meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol 2022;12:821802. [DOI: 10.3389/fphar.2021.821802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Shiha MG, Aziz I. Review article: Physical and psychological comorbidities associated with irritable bowel syndrome. Aliment Pharmacol Ther 2021;54 Suppl 1:S12-23. [PMID: 34927759 DOI: 10.1111/apt.16589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Nee J, Lembo A. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). Aliment Pharmacol Ther 2021;54 Suppl 1:S63-74. [PMID: 34927757 DOI: 10.1111/apt.16625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Luo Y, Keefer L. Role of psychological questionnaires in clinical practice and research within functional gastrointestinal disorders. Neurogastroenterol Motil 2021;33:e14297. [PMID: 34786802 DOI: 10.1111/nmo.14297] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Masclee GMC, Snijkers JTW, Boersma M, Masclee AAM, Keszthelyi D. Patient preferences of healthcare delivery in irritable bowel syndrome: a focus group study. BMC Gastroenterol 2021;21:438. [PMID: 34814846 DOI: 10.1186/s12876-021-02030-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Villegas MA, Okenfuss E, Savarirayan R, White K, Hoover-Fong J, Bober MB, Duker A, Legare JM. Multidisciplinary Care of Neurosurgical Patients with Genetic Syndromes. Neurosurg Clin N Am 2022;33:7-15. [PMID: 34801144 DOI: 10.1016/j.nec.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Shiha MG, Asghar Z, Thoufeeq M, Kurien M, Ball AJ, Rej A, Tai FWD, Afify S, Aziz I. Increased psychological distress and somatization in patients with irritable bowel syndrome compared with functional diarrhea or functional constipation, based on Rome IV criteria. Neurogastroenterol Motil 2021;33:e14121. [PMID: 33719130 DOI: 10.1111/nmo.14121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Shapiro JM, Deutsch JK. Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome. Gastroenterol Clin North Am 2021;50:671-88. [PMID: 34304794 DOI: 10.1016/j.gtc.2021.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Moshiree B, Talley NJ. Functional dyspepsia: A critical appraisal of the European consensus from a global perspective. Neurogastroenterol Motil 2021;33:e14216. [PMID: 34337832 DOI: 10.1111/nmo.14216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Berry SK, Chey WD. Integrated Care for Irritable Bowel Syndrome: The Future Is Now. Gastroenterol Clin North Am 2021;50:713-20. [PMID: 34304796 DOI: 10.1016/j.gtc.2021.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Daly M, Zarate-Lopez N. Functional gastrointestinal disorders: History taking skills in practice. Clin Med (Lond) 2021;21:e480-6. [PMID: 34385299 DOI: 10.7861/clinmed.2021-0189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Schwille-Kiuntke J, Rüdlin SL, Junne F, Enck P, Brenk-Franz K, Zipfel S, Rieger MA. Illness perception and health care use in individuals with irritable bowel syndrome: results from an online survey. BMC Fam Pract 2021;22:154. [PMID: 34275465 DOI: 10.1186/s12875-021-01499-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, Agrawal A, Aziz I, Farmer AD, Eugenicos MP, Moss-Morris R, Yiannakou Y, Ford AC. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021;70:1214-40. [PMID: 33903147 DOI: 10.1136/gutjnl-2021-324598] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 42.5] [Reference Citation Analysis]
33 Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:1485-94. [PMID: 33840729 DOI: 10.14309/ajg.0000000000001247] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
34 Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond) 2021;21:44-52. [PMID: 33479067 DOI: 10.7861/clinmed.2020-0980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
35 Sasegbon A, Vasant DH. Understanding racial disparities in the care of patients with irritable bowel syndrome: The need for a unified approach. Neurogastroenterol Motil 2021;33:e14152. [PMID: 33835634 DOI: 10.1111/nmo.14152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Sasegbon A, Vasant DH. Highlights from the literature. Frontline Gastroenterol 2021;12:255-6. [DOI: 10.1136/flgastro-2020-101773] [Reference Citation Analysis]
37 Heinrich H. Low-FODMAP-Diät – Lösung aller Probleme? Schweiz Gastroenterol 2021;2:24-29. [DOI: 10.1007/s43472-021-00035-1] [Reference Citation Analysis]
38 Duncanson K, Burns G, Pryor J, Keely S, Talley NJ. Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia. Nutrients 2021;13:1109. [PMID: 33800668 DOI: 10.3390/nu13041109] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
39 Rafferty AJ, Hall R, Johnston CS. A Novel Mobile App (Heali) for Disease Treatment in Participants With Irritable Bowel Syndrome: Randomized Controlled Pilot Trial (Preprint).. [DOI: 10.2196/preprints.24134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Chey WD. Integrated care for disorders of gut-brain interaction. Lancet Gastroenterol Hepatol 2020;5:876-7. [PMID: 32679041 DOI: 10.1016/S2468-1253(20)30235-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]